Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Protara Therapeutics (TARA) Return on Capital Employed (2016 - 2026)

Protara Therapeutics' Return on Capital Employed history spans 13 years, with the latest figure at 36.53% for Q1 2026.

  • Quarterly Return on Capital Employed fell 592.0% to 36.53% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 36.53% through Mar 2026, down 592.0% year-over-year, with the annual reading at 34.98% for FY2025, 624.0% up from the prior year.
  • Return on Capital Employed came in at 36.53% for Q1 2026, up from 38.86% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 25.56% in Q3 2022 to a low of 84.77% in Q3 2023.
  • The 5-year median for Return on Capital Employed is 42.44% (2025), against an average of 47.59%.
  • Year-over-year, Return on Capital Employed tumbled -5921bps in 2023 and then soared 3660bps in 2025.
  • Protara Therapeutics' Return on Capital Employed stood at 53.56% in 2022, then fell by -5bps to 56.23% in 2023, then skyrocketed by 31bps to 38.76% in 2024, then fell by 0bps to 38.86% in 2025, then grew by 6bps to 36.53% in 2026.
  • Per Business Quant, the three most recent readings for TARA's Return on Capital Employed are 36.53% (Q1 2026), 38.86% (Q4 2025), and 42.44% (Q3 2025).